Tortugas Neuroscience
PrivateLast Round
Series A
Aug 3, 2026
Total Funding Raised
$151M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Tortugas Neuroscience is a biotechnology company that develops novel medicines for neurological and neuropsychiatric disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tortugas Neuroscience Comparables
Compare Tortugas Neuroscience with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Leal Therapeutics | 85% | |
| MapLight Therapeutics | 78% | |
| Minerva Neurosciences | 77% |
Tortugas Neuroscience Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Aug 3, 2026 | ||||
| Series A | Apr 21, 2026 |
Tortugas Neuroscience Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Column Group | Series A |
| AN Venture Partners | Series A |
| Cure Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 3, 2026
$76M round led by AN Venture Partners and The Column Group.
- Apr 21, 2026
$106M round closed
Recent news
Latest coverage and updates
- hiresSep 9, 2026
Tortugas Neuroscience, Inc. hired Jim Frates as director and Audit Committee chair on Sep 9th '26.
Tortugas Neuroscience Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access